Industry news

Biosimilar medicines news

09

December 2024

Medicines for Europe calls on the EU to take strategic action on generics and biosimilars

09 2024 December Biosim

Blog post

14

May 2024

“We cannot talk about innovation and sustainability without talking about biosimilars”

14 May 2024 Biosim

Blog post

26

Apr 2024

Biosimilars, the democratization of medicines

Apr 26 2024 Biosim

Blog post

01

Márta 2024

Europe dedicated more than 8.000 million euros to the purchase of biosimilars

March 01 2024 Biosim

Blog post

21

February 2024

Saving on healthcare no longer requires stopping investment in drugs

Feb 21 2024 Biosim

Blog post

11

February 2024

The role of nurses in the use of biosimilar medicines

Feb 11 2024 Biosim

Blog post

08

Jan 2024

Biosimilars: the key to access to health

Jan 08 2024 Biosim

Blog post

01

Jan 2024

The Ministry of Health considers the possibility of creating an observatory for biosimilars

Jan 01 2024 Biosim

Blog post

04

December 2023

“Biotechnology is revolutionizing the world”

04 2023 December Biosim

Blog post

23

November 2023

Andalusia analyzes the implementation of biosimilars in its health system

November 23 2023 Biosim

Blog post

06

October 2023

Why do biosimilar medicines matter to the Economy?

October 06 2023 Biosim

Blog post

23

Sep 2023

Improving the efficiency of the health system through the use of biosimilars

23 September 2023 Biosim

Blog post

26

Christmas

The CHMP of the European Medicines Agency recommends three new biosimilars

Jul 26 2023 Biosim

Blog post

13

Christmas

Who wins and who loses from the end of biopharmaceutical patents?

Jul 13 2023 Biosim

Blog post

12

Christmas

Biosimilar insulin glargine contributes to the sustainability of the National Health System

Jul 12 2023 Biosim

Blog post

19

Meitheamh 2023

New broadcast of OAFI Radio, with its section on biosimilar medicines

19 June 2023 Biosim

Blog post

14

Meitheamh 2023

Biosimilar medications, more important and present in your life than you think

14 June 2023 Biosim

Blog post

07

Meitheamh 2023

OCU calls for increasing the use of biosimilar medicines in Spain

07 June 2023 Biosim

Blog post

06

Meitheamh 2023

Two eculizumab biosimilars bring those authorized in Europe to 76

06 June 2023 Biosim

Blog post

11

May 2023

The CIMP proposes the financing of the first biosimilar medicine of the active ingredient eculizumab

11 May 2023 Biosim

Blog post

02

May 2023

The Balearic Islands puts out to tender the acquisition of biosimilar medicines for its health service

02 May 2023 Biosim

Blog post

24

Apr 2023

Biosimilars, an engine of innovation

Apr 24 2023 Biosim

Blog post

28

Márta 2023

Navarra reduces the impact of hospital pharmaceutical spending by 20 million with the use of biosimilar medicines in the last three years

March 28 2023 Biosim

Blog post

07

February 2023

Biosimilars and beyond: innovating to improve patient outcomes

Feb 07 2023 Biosim

Blog post

13

Jan 2023

UK updates its guideline to allow interchangeability of biosimilars

Jan 13 2023 Biosim

Blog post

08

December 2022

Switching to adalimumab biosimilar in the treatment of rheumatoid arthritis: how the patient perceives it

08 2022 December Biosim

Blog post

29

November 2022

Biosimilar insulin glargine has a lower risk of hypoglycemia

November 29 2022 Biosim

Blog post

24

November 2022

The Ministry of Health awards the biosimilar tender among 13 laboratories

November 24 2022 Biosim

Blog post

10

November 2022

The use of biosimilars saves Aragon 40 million in pharmaceutical spending

November 10 2022 Biosim

Blog post

05

November 2022

The Ministry of Health presents the campaign "Effective for you, effective for Health"

November 05 2022 Biosim

Blog post

04

November 2022

The loss of patents leaves a market of more than 33.000 million in Europe

November 04 2022 Biosim

Blog post

27

October 2022

The time to develop a biosimilar ranges from six to twelve years

October 27 2022 Biosim

Blog post

20

October 2022

Improving patient acceptance of biosimilars through health psychology

October 20 2022 Biosim

Blog post

20

October 2022

The autonomous province of Saskatchewan develops a specific policy on biosimilars

October 20 2022 Biosim

Blog post

19

October 2022

Castilla - La Mancha establishes new objectives in biosimilars

October 19 2022 Biosim

Blog post

07

October 2022

Biosimilars do not have clinically significant differences with the reference product

October 07 2022 Biosim

Blog post

04

October 2022

What are biosimilar medicines and why are they needed in public health systems?

October 04 2022 Biosim

Blog post

29

Sep 2022

Biosimilars, biological drugs that lower the cost of treatments

29 September 2022 Biosim

Blog post

22

Sep 2022

Primary pharmacists will have an "essential and strategic" role in the dissemination of biosimilars in primary care

22 September 2022 Biosim

Blog post

19

Sep 2022

EMA position on interchangeability

19 September 2022 Biosim

Blog post

06

Sep 2022

The Ministry of Health begins the processing of the OPR of 2022, which creates 30 sets, including several of biosimilars

06 September 2022 Biosim

Blog post

24

Aug 2022

Review of clinical evidence on the exchange in biosimilars

August 24 2022 Biosim

Blog post

19

Christmas

Analysis of the savings for the Medicare system from the use of biosimilars

Jul 19 2022 Biosim

Blog post

15

Christmas

Biosimilars save Spain more than 5.000 million euros between 2009 and 2022

Jul 15 2022 Biosim

Blog post

05

Christmas

Biosimilar medicines

Jul 05 2022 Biosim

Blog post

17

Meitheamh 2022

Biosimilar insulin: similar efficacy and safety

17 June 2022 Biosim

Blog post

03

Meitheamh 2022

Almost 60% of patients do not have sufficient knowledge about biosimilar medicines

03 June 2022 Biosim

Blog post

18

May 2022

A biosimilar is analogous and equivalent to a biologic.

18 May 2022 Biosim

Blog post

05

May 2022

15 companies present their offers to the INGESA Biosimilars Framework Agreement

05 May 2022 Biosim

Blog post

23

Apr 2022

Value-based contracting, a challenge for the industry and the administration

Apr 23 2022 Biosim

Blog post

21

Apr 2022

Biosimilar insulins reduce HbA1c with less risk of hypoglycemia

Apr 21 2022 Biosim

Blog post

31

Márta 2022

Biosimilars in psoriasis: accessibility and safety, above all

March 31 2022 Biosim

Blog post

23

Márta 2022

INGESA, from the Ministry of Health, publishes the new competition for biosimilar drugs

March 23 2022 Biosim

Blog post

18

Márta 2022

The CSC brought together healthcare managers to discuss the benefits of profit sharing in healthcare management

March 18 2022 Biosim

Blog post

17

Márta 2022

Spain needs a plan for the second biosimilar revolution

March 17 2022 Biosim

Blog post

16

February 2022

"With biosimilars we treat patients just as well as with original biologics"

Feb 16 2022 Biosim

Blog post

11

Jan 2022

The FDA authorized four new biosimilars in 2021

Jan 11 2022 Biosim

Blog post

05

Jan 2022

Health news in France for 2022: renewal of incentives for a larger group of biosimilars

Jan 05 2022 Biosim

Blog post

24

December 2021

INGESA, from the Ministry of Health, puts out to tender the purchase of biosimilar drugs for 253 million

24 2021 December Biosim

Blog post

03

December 2021

"Switch" of adalimumab for its biosimilar in a third level hospital

03 2021 December Biosim

Blog post

03

December 2021

Inflammatory diseases widen the hospital market for biologic drugs

03 2021 December Biosim

Blog post

22

November 2021

The Mayo Clinic applies the "biosimilar first" criterion

November 22 2021 Biosim

Blog post

18

November 2021

Catalonia advances with a biosimilar prescription quota of 80% in naïve patients

November 18 2021 Biosim

Blog post

03

November 2021

Investment and collaboration, necessary axes for the pharmaceutical industry

November 03 2021 Biosim

Blog post

29

October 2021

Why Biosimilars Facilitate Access for Psoriasis Patients

October 29 2021 Biosim

Blog post

28

October 2021

Biosimilars in oncology. Current situation. New challenges, new opportunities

October 28 2021 Biosim

Blog post

20

October 2021

FDA approves its second interchangeable biosimilar for the United States

October 20 2021 Biosim

Blog post

13

October 2021

The General State Budgets will include a plan for the rationalization of pharmaceutical consumption with reference to biosimilars

October 13 2021 Biosim

Blog post

30

Sep 2021

Biosimilars in the update of the list of essential medicines of the WHO

30 September 2021 Biosim

Blog post

30

Aug 2021

The Generic and Biosimilar Medicines Plan raises doubts about its long-term efficacy

August 30 2021 Biosim

Blog post

28

Christmas

First FDA-approved interchangeable insulin biosimilar

Jul 28 2021 Biosim

Blog post

27

May 2021

Monserrat calls for more investment and new business models in the new EU Pharmaceutical Strategy

27 May 2021 Biosim

Blog post

20

Apr 2021

"The market share of biosimilars can be greatly improved"

Apr 20 2021 Biosim

Blog post

13

Apr 2021

Fifteen years of accumulated evidence support biosimilar medicines in the European Union

Apr 13 2021 Biosim

Blog post

06

Apr 2021

Dr. Albanell: The incorporation of biosimilars into clinical practice is being "quite important"

Apr 06 2021 Biosim

Blog post

29

Márta 2021

Valencia approves the first centralized purchase of biosimilars for health centers

March 29 2021 Biosim

Blog post

16

Jan 2021

200 pharmacists participate in the Micof 'webinar' on co-payment, biosimilars and notified prices

Jan 16 2021 Biosim

Blog post

08

Jan 2021

The CNMC starts a public consultation on medicines in pharmacies

Jan 08 2021 Biosim

Blog post

09

October 2020

Improving the measurement of results would promote the use of biosimilars

October 09 2020 Biosim

Blog post

01

October 2020

AIReF proposes efficiency improvements in spending on hospital pharmacy and investment planning in technology that allows us to converge to the average of OECD countries

October 01 2020 Biosim

Blog post

23

Sep 2020

Biosimilars: effective treatments at lower cost

23 September 2020 Biosim

Blog post

05

Sep 2020

Biosimilarity: a novel approach to developing therapeutics and vaccines for COVID-19

05 September 2020 Biosim

Blog post

11

Aug 2020

Andalusia announces a tender for nine biosimilars for 218 million

August 11 2020 Biosim

Blog post

22

Christmas

Biosimilar Interchangeability: A Global Perspective for Pharmacists

Jul 22 2020 Biosim

Blog post

06

Márta 2020

Biosimilar penetration doubles in just one year

March 06 2020 Biosim

Blog post

11

November 2019

Summary position of BioSim to the "Action Plan to Promote the Use of Market Regulatory Medicines in the SNS: Biosimilar Medicines and Drugs

November 11 2019 Biosim

Blog post

13

Meitheamh 2019

Biosimilars are positioned as an option to increase access to effective and safe treatments in rheumatic diseases

13 June 2019 Biosim

Blog post

03

Meitheamh 2019

What are the keys to Castilla-La Mancha's leadership in biosimilars?

03 June 2019 Biosim

Blog post

28

February 2019

Asturias creates a guide to promote the use of biosimilars

Feb 28 2019 Biosim

Blog post

26

February 2019

The pharmacist, key in the adherence of biosimilars

Feb 26 2019 Biosim

Blog post

25

February 2019

Health considers biosimilars a "priority" for sustainability

Feb 25 2019 Biosim

Blog post

25

February 2019

The Ministry of Health will train citizens on active, generic or biosimilar ingredients

Feb 25 2019 Biosim

Blog post

17

October 2018

The use of biosimilars reaches 43% in hospitals in Castilla y León

October 17 2018 Biosim

Blog post

02

October 2018

Biosimilar penetration is irregular in SNS hospitals

October 02 2018 Biosim

Blog post

02

October 2018

The growth of biosimilar drugs will allow savings of 2.000 million annually

October 02 2018 Biosim

Blog post

28

Sep 2018

Oncologists highlight the value of biosimilars for access

28 September 2018 Biosim

Blog post

25

Christmas

The FDA will create a 'comparator' of biosimilars and reference drugs

Jul 25 2018 Biosim

Blog post

24

Christmas

Biosimilar prescription

Jul 24 2018 Biosim

Blog post

23

Christmas

The FDA publishes the 'Biosimilars Action Plan', with the aim of accelerating innovation

Jul 23 2018 Biosim

Blog post

23

Christmas

Eleven new biosimilars will arrive in the short term, six for the pharmacy

Jul 23 2018 Biosim

Blog post

23

Christmas

BIOSIMILAR ACTION PLAN: balance between innovation and competition

Jul 23 2018 Biosim

Blog post

20

Christmas

BioSim and Aeseg celebrate Montón's support for their sectors

Jul 20 2018 Biosim

Blog post

19

Christmas

The US outlines the four pillars of its new Biosimilars Plan

Jul 19 2018 Biosim

Blog post

19

Christmas

Catalonia: the Department of Health teaches biosimilars

Jul 19 2018 Biosim

Blog post

13

Christmas

Switching from Reference Adalimumab to Biosimilar ABP 501 Does Not Cause Immunogenicity

Jul 13 2018 Biosim

Blog post

13

Christmas

The Canarian strategy in biosimilars brings the clinical decision to the fore

Jul 13 2018 Biosim

Blog post

12

Christmas

The Indukern Group invested more than 70 million in projects to strengthen its activity

Jul 12 2018 Biosim

Blog post

10

Christmas

Medicines for Europe: better access, better health

Jul 10 2018 Biosim

Blog post

09

Christmas

The FFOMC courses on Smoking, Biosimilars and MIR Tutors bring together more than 1.400 students

Jul 09 2018 Biosim

Blog post

09

Christmas

Biosimilars in Murcia: two departments of each hospital must promote them

Jul 09 2018 Biosim

Blog post

05

Christmas

Biosimilars: a value bet

Jul 05 2018 Biosim

Blog post

04

Christmas

The biosimilar maintains therapeutic efficacy and does not increase the risks

Jul 04 2018 Biosim

Blog post

03

Christmas

Samsung Bioepis: Translating the "hunger" for biosimilars to new medicines

Jul 03 2018 Biosim

Blog post

29

Meitheamh 2018

Amneal and mAbxience reach agreement for biosimilar bevacizumab

29 June 2018 Biosim

Blog post

08

Meitheamh 2018

Interview of the international magazine Pharma Boardroom with Regina Múzquiz, General Director of BioSim

08 June 2018 Biosim

Blog post

04

December 2017

FDA grants approval of the first biosimilar for the treatment of patients with breast and stomach cancer

04 2017 December Biosim

Blog post

03

December 2017

Galicia sets a 40 percent target in new biosimilars

03 2017 December Biosim

Blog post

28

November 2017

Specialist doctors are trained in a Course on Biosimilars

November 28 2017 Biosim

Blog post

24

October 2017

CYL highlights its "determined and prudent" commitment to biosimilars

October 24 2017 Biosim

Blog post

23

October 2017

FDA takes an active role in promoting the use of biosimilar medicines

October 23 2017 Biosim

Blog post

15

October 2017

Infographic: Biosimilar Pegfilgrastim

October 15 2017 Biosim

Blog post

13

October 2017

Quiz: the use of biosimilars to treat rheumatic diseases

October 13 2017 Biosim

Blog post

13

October 2017

Recommendations for the use of biosimilars in rheumatic diseases

October 13 2017 Biosim

Blog post

13

October 2017

Murcia establishes criteria to promote the use of biosimilars

October 13 2017 Biosim

Blog post

10

October 2017

Marc Alexander Mahl, new president of Medicines for Europe

October 10 2017 Biosim

Blog post

09

October 2017

Biosimilars in Europe

October 09 2017 Biosim

Blog post

09

October 2017

Are biosimilar drugs the future of cancer treatment?

October 09 2017 Biosim

Blog post

09

October 2017

Two out of three Spaniards have taken medication in the last 15 days

October 09 2017 Biosim

Blog post

08

October 2017

Infographic: consensus recommendations on biosimilars in rheumatology

October 08 2017 Biosim

Blog post

08

May 2017

Biosimilars in the European Union – Information guide for healthcare professionals

08 May 2017 Biosim

Blog post

16

December 2016

“The beginnings of biosimilars were complicated”

16 2016 December Biosim

Blog post

16

December 2016

"With new patients there is no discussion, you have to use the biosimilar"

16 2016 December Biosim

Blog post

16

December 2016

“Experience shows that there is no difference between biological and biosimilar”

16 2016 December Biosim

Blog post

16

December 2016

"The initial uncertainty has changed to an attitude convinced of its use"

16 2016 December Biosim

Blog post

14

December 2016

Biogen launches two biosimilars to be a 'partner' in cost containment

14 2016 December Biosim

Blog post

14

December 2016

Biosimilars provide therapeutic alternatives, safety and savings to the SNS

14 2016 December Biosim

Blog post

14

December 2016

Italian finance account for 2017: Important news related to biosimilars

14 2016 December Biosim

Blog post

12

December 2016

New statement from the European Crohn's Disease and Colitis Organization supports the use of biosimilars instead of reference products to treat intestinal inflammations

12 2016 December Biosim

Blog post

09

December 2016

Italy: Competition gives a touch to biologics bidding measures

09 2016 December Biosim

Blog post

09

December 2016

Biologicals and biosimilars. clarifying concepts

09 2016 December Biosim

Blog post

09

December 2016

Global pharmaceutical spending will reach $2021 trillion by XNUMX

09 2016 December Biosim

Blog post

09

December 2016

Medicines for Europe calls for recognition of the value offered by generics and biosimilars

09 2016 December Biosim

Blog post

09

December 2016

Three congresses augur promising advances in the global fight against cancer

09 2016 December Biosim

Blog post

05

December 2016

The Aemps asks to review the drug laws

05 2016 December Biosim

Blog post

05

December 2016

Biosimilars, a formula to sustain the healthcare system

05 2016 December Biosim

Blog post

02

December 2016

“Now is not the time to talk about compensation for professional services”

02 2016 December Biosim

Blog post

01

December 2016

35% of oncologists see specific studies on biosimilars as unnecessary

01 2016 December Biosim

Blog post

23

November 2016

Study sees equivalent to Enbrel and Sandoz's etanercept biosimilar

November 23 2016 Biosim

Blog post

22

November 2016

BioSim inaugurates its new headquarters in Madrid

November 22 2016 Biosim

Blog post

22

November 2016

Study reveals that the biosimilar etanercept has equivalent efficacy to the original

November 22 2016 Biosim

Blog post

22

November 2016

Biosim inaugurates its new offices in Madrid

November 22 2016 Biosim

Blog post

18

November 2016

The EMA issues a positive opinion for Steriparatide

November 18 2016 Biosim

Blog post

11

November 2016

Boehringer Ingelheim already has its first biosimilar ready

November 11 2016 Biosim

Blog post

10

November 2016

Biosim will deal with the CCAA formulas to ensure the market for the biosimilar

November 10 2016 Biosim

Blog post

09

November 2016

José Luis Andreu, president of the SER: with new patients there is no discussion, you have to use the biosimilar

November 09 2016 Biosim

Blog post

07

November 2016

Reflections on biosimilar medicines in the 64th day of FUINSA

November 07 2016 Biosim

Blog post

07

November 2016

Boehringer Ingelheim on the brink of submitting its first biosimilar to the regulator

November 07 2016 Biosim

Blog post

06

November 2016

Spanish doctors demand more training in biosimilars

November 06 2016 Biosim

Blog post

05

November 2016

The myth of German biosimilar quotas

November 05 2016 Biosim

Blog post

04

November 2016

Clinicians ask for more evidence to exchange originals for biosimilars

November 04 2016 Biosim

Blog post

04

November 2016

Dialogue and a good team, the sector's first message to Dolors Montserrat

November 04 2016 Biosim

Blog post

04

November 2016

Take the reins of a Ministry with the inkwell loaded with legislative emergencies

November 04 2016 Biosim

Blog post

03

November 2016

Scientific societies show their coincidences in biosimilars

November 03 2016 Biosim

Blog post

28

October 2016

Regina Múzquiz (BioSim): Specific regulations are needed to regulate the use of biosimilars

October 28 2016 Biosim

Blog post

27

October 2016

58% of family doctors would not know how to correctly define what a biosimilar is

October 27 2016 Biosim

Blog post

25

October 2016

Biosimilars: Extremadura, contrary to "massive changes" in therapies already underway

October 25 2016 Biosim

Blog post

21

October 2016

How to promote the biosimilar without hindering the freedom of prescription?

October 21 2016 Biosim

Blog post

21

October 2016

The Treasury promises Brussels an adjustment of 550 million in pharmaceutical spending

October 21 2016 Biosim

Blog post

21

October 2016

Community pharmacy, pharmaceutical industry and distribution highlight their contribution to the sustainability of the health system

October 21 2016 Biosim

Blog post

20

October 2016

Community pharmacy, industry and distribution endorse the contribution of the profession to the sustainability of the SNS

October 20 2016 Biosim

Blog post

19

October 2016

The sustainability of the pharmaceutical service goes through a political pact

October 19 2016 Biosim

Blog post

19

October 2016

Celltrion Healthcare: NOR-SWITCH, The Norwegian Government's Independent Study, Supports Switching From Original Infliximab To Biosimilar Infliximab

October 19 2016 Biosim

Blog post

18

October 2016

Rogelio Ambrosi: "Before the end of the year we will decide if Merck opens another plant in Madrid"

October 18 2016 Biosim

Blog post

10

October 2016

The European will continue to be the first market for biosimilars in 2020

October 10 2016 Biosim

Blog post

07

October 2016

BioSim's challenge is normative: modify the Law of Guarantees and future RDs

October 07 2016 Biosim

Blog post

07

October 2016

Portugal requires hospitals a minimum quota for biosimilars of 20%

October 07 2016 Biosim

Blog post

07

October 2016

The SER ensures that biosimilars will improve the "efficiency" of the SNS

October 07 2016 Biosim

Blog post

29

Sep 2016

“It is better to generate trust towards biosimilars than to force their prescription”

29 September 2016 Biosim

Blog post

19

Sep 2016

Regina Múzquiz: "It is vital to manage the expectations of the biosimilar well"

19 September 2016 Biosim

Blog post

16

Sep 2016

The emergence of biosimilars in the EU reduces prices by up to 26%

16 September 2016 Biosim

Blog post

12

Sep 2016

Biosim will present to the Government a draft standard for biosimilars

12 September 2016 Biosim

Blog post

08

Sep 2016

NICE will not distinguish between original biologics and their biosimilars

08 September 2016 Biosim

Blog post

31

Aug 2016

There are already three biosimilars approved by the FDA

August 31 2016 Biosim

Blog post

30

Aug 2016

Mylan registers a biosimilar in the EU that will face a Roche bestseller

August 30 2016 Biosim

Blog post

16

Aug 2016

The EMA promotes better control of biological medicines

August 16 2016 Biosim

Blog post

04

Aug 2016

«Biosimilar drugs are up to 30% cheaper than the originals»

August 04 2016 Biosim

Blog post

26

Christmas

Biological drugs get the first consensus of the legislature

Jul 26 2016 Biosim

Blog post

22

Christmas

"We have met the deficit target and we do not accept being taught lessons"

Jul 22 2016 Biosim

Blog post

18

Christmas

A standard that can be modernized but with full force

Jul 18 2016 Biosim

Blog post

08

Christmas

Portugal 'primes' itself with filgrastim to generate savings for its system

Jul 08 2016 Biosim

Blog post

04

Christmas

The mAbxience plant in León completes the manufacture of its first batch of biosimilars

Jul 04 2016 Biosim

Blog post

24

Meitheamh 2016

Health offers the RD of Prices in order to regulate biologicals

24 June 2016 Biosim

Blog post

22

Meitheamh 2016

Sandoz plans to launch five new biosimilars by 2020

22 June 2016 Biosim

Blog post

27

May 2016

We are going to favor the introduction of biosimilars; is a logical trend

27 May 2016 Biosim

Blog post

23

May 2016

Dialogue and consensus to build the future

23 May 2016 Biosim

Blog post

11

May 2016

Science to Business Conference. Success stories in the development of innovators and biosimilars

11 May 2016 Biosim

Blog post

06

May 2016

Medicines for Europe expects 50 new biosimilars to be launched on the market by 2020

06 May 2016 Biosim

Blog post

06

May 2016

"In the biosimilar sector in Spain we have the opportunity to do well"

06 May 2016 Biosim

Blog post

25

Apr 2016

Boehringer grows and entrusts its future to its own and collaborative innovation

Apr 25 2016 Biosim

Blog post

25

Apr 2016

The choice of the biological, better, agreed between professionals

Apr 25 2016 Biosim

Blog post

22

Apr 2016

Valencia will entrust the savings in pharmacy to the centralized purchase and the use of biosimilars

Apr 22 2016 Biosim

Blog post

18

Apr 2016

FDA guidelines for the labeling of biosimilars, upon request

Apr 18 2016 Biosim

Blog post

15

Apr 2016

Accord launches Accofil, its biosimilar for neutropenia and febrile neutropenia

Apr 15 2016 Biosim

Blog post

14

Apr 2016

Tecnoquímicas enters the business of biosimilar medicines

Apr 14 2016 Biosim

Blog post

14

Apr 2016

Biosimilars establish themselves as a decisive factor for SNS sustainability

Apr 14 2016 Biosim

Blog post

12

Apr 2016

The EC gives its 'OK' to the subcutaneous administration of Binocrit, from Sandoz

Apr 12 2016 Biosim

Blog post

08

Apr 2016

US approves first biosimilar monoclonal antibody

Apr 08 2016 Biosim

Blog post

08

Apr 2016

FDA Releases Guidance on Biosimilar Labeling

Apr 08 2016 Biosim

Blog post

04

Apr 2016

Galicia is committed to introducing biosimilars in primary care

Apr 04 2016 Biosim

Blog post

01

Apr 2016

The biosimilar shows its potential as a tool for access and savings

Apr 01 2016 Biosim

Blog post

29

Márta 2016

Joaquín Rodrigo: "If you only seek sustainability in the short term, there will be no biosimilars in the future"

March 29 2016 Biosim

Blog post

29

Márta 2016

Improves the confidence of professionals in biosimilars

March 29 2016 Biosim

Blog post

29

Márta 2016

The development of biosimilar medicines could save up to 98 million euros in 2020

March 29 2016 Biosim

Blog post

16

Márta 2016

Diariofarma brings biosimilars closer to Health parliamentarians

March 16 2016 Biosim

Blog post

11

Márta 2016

The EGA is renamed Medicines for Europe

March 11 2016 Biosim

Blog post

11

Márta 2016

Valencia wants a 25% quota for biosimilars

March 11 2016 Biosim

Blog post

10

Márta 2016

mAbxience will develop Synagis, AbbVie's biosimilar, together with the University of Utrecht

March 10 2016 Biosim

Blog post

07

Márta 2016

The price of the biosimilar, decisive for the future of the market

March 07 2016 Biosim

Blog post

07

Márta 2016

The pharmaceutical sector wants stable regulatory and economic frameworks

March 07 2016 Biosim

Blog post

18

February 2016

Political uncertainty is bad for the biosimilar

Feb 18 2016 Biosim

Blog post

11

February 2016

EMA accepts Sandoz's registration application for a pegfilgrastim biosimilar

Feb 11 2016 Biosim

Blog post

11

February 2016

Valencia: centralized purchases, biosimilars and cost-effectiveness, strategies to save

Feb 11 2016 Biosim

Blog post

09

February 2016

Interview of the Farmacéuticos Magazine with Joaquín Rodrigo, President of BioSim

Feb 09 2016 Biosim

Blog post

25

Jan 2016

The EMA has authorized 19 biosimilars of 9 active substances and 11 companies

Jan 25 2016 Biosim

Blog post

25

Jan 2016

The 'fingerprint' of biotechnologists

Jan 25 2016 Biosim

Blog post

21

Jan 2016

EU 'yes' to etanercept biosimilar

Jan 21 2016 Biosim

Blog post

11

Jan 2016

Biosimilars manage to democratize access to new therapies in the European Union

Jan 11 2016 Biosim

Blog post

07

Jan 2016

Public spending on hospitals will be the target of the next health adjustment

Jan 07 2016 Biosim

Blog post

22

December 2015

Biosimilars: more and better access to leading medicines

22 2015 December Biosim

Blog post

18

December 2015

Patients are essential actors in denouncing automatic substitution

18 2015 December Biosim

Blog post

10

December 2015

Biosimilars already have a unique voice in Spain

10 2015 December Biosim

Blog post

30

November 2015

EMA gives the go-ahead for Samsung Bioepis' version of etanercept

November 30 2015 Biosim

Blog post

30

November 2015

Rheumatologists underline the savings that biosimilars will bring to the NHS

November 30 2015 Biosim

Blog post

29

November 2015

"In the short term, a specific legislative framework for biosimilars is necessary"

November 29 2015 Biosim

Blog post

27

November 2015

Oncologists prepare the arrival of the first biosimilars

November 27 2015 Biosim

Blog post

27

November 2015

“Biosimilars must be incorporated into the system to stay”

November 27 2015 Biosim

Blog post

23

November 2015

"Clear legislation would promote the production of biosimilars in Spain"

November 23 2015 Biosim

Blog post

23

November 2015

Incentivize the biosimilar to 'help' its prescription

November 23 2015 Biosim

Blog post

21

November 2015

“If there is no specific regulatory framework, there will be no biosimilars in the future”

November 21 2015 Biosim

Blog post

20

November 2015

"If only savings are taken into account, there will be no biosimilars in the future"

November 20 2015 Biosim

Blog post

17

November 2015

"The biosimilar should not be seen only as short-term savings"

November 17 2015 Biosim

Blog post

17

November 2015

"The biosimilar needs legislation that recognizes its uniqueness"

November 17 2015 Biosim

Blog post

06

November 2015

Health supports BioSim and highlights the saving power of biosimilars

November 06 2015 Biosim

Blog post

06

November 2015

With an open heart: BioSim, for the quality and sustainability of the SNS

November 06 2015 Biosim

Blog post

04

November 2015

The SER ensures that the trust of the doctor is the key to a "correct" implantation of biosimilars

November 04 2015 Biosim

Blog post

03

November 2015

BioSim, the Spanish Association of Biosimilars, is born

November 03 2015 Biosim

Blog post

03

November 2015

The entire biosimilars industry unites around Biosim

November 03 2015 Biosim

Blog post

03

November 2015

A new association of biosimilar drug companies is born

November 03 2015 Biosim

Blog post

03

November 2015

A new business association comes to reinforce the role of Biosimilars

November 03 2015 Biosim

Blog post

03

November 2015

Biosim presents itself in society

November 03 2015 Biosim

Blog post

03

November 2015

Biosim is born, with a vocation to integrate EFG and brands

November 03 2015 Biosim

Blog post

03

November 2015

Biosimilars will save up to 400 million euros in five years

November 03 2015 Biosim

Blog post

30

October 2015

The inauguration of the new employers' association Biosim augurs a new panorama in the industry

October 30 2015 Biosim

Blog post

24

October 2015

Interview with Marc Comas, "this year we will double our turnover in Spain, up to 30 million"

October 24 2015 Biosim

Blog post

17

October 2015

The Mabxience plant in Leon would yield 100% as of 2020

October 17 2015 Biosim

Blog post

09

October 2015

Cinfa Biotech begins clinical trials to develop its first biosimilar

October 09 2015 Biosim

Blog post

09

October 2015

The Aemps identifies the arrival of new monoclonal antibodies as a challenge for the SNS

October 09 2015 Biosim

Blog post

07

October 2015

Boehringer Ingelheim and Lilly launch the first biosimilar insulin in Spain

October 07 2015 Biosim

Blog post

02

October 2015

Patent loss calls for specific regulation on biosimilars

October 02 2015 Biosim

Blog post

20

Apr 2015

Health will study how to strengthen the safety of biosimilars

Apr 20 2015 Biosim

Blog post

11

Apr 2015

The second patents worry the EGA

Apr 11 2015 Biosim

Blog post

01

Apr 2015

"I would like biosimilars to be a strategic necessity in health plans"

Apr 01 2015 Biosim

Blog post

20

Márta 2015

Europe prepares for the expiration of four biological patents during 2015

March 20 2015 Biosim

Blog post

09

Márta 2015

The national biosimilars industry calls for a favorable framework to be able to be competitive

March 09 2015 Biosim

Blog post

02

February 2015

IMS estimates the biosimilar business at 1.500 million until 2020

Feb 02 2015 Biosim

Blog post

23

Jan 2015

With an open heart: Biosimilars, a unique opportunity

Jan 23 2015 Biosim

Blog post

12

Jan 2015

Precision medicines and biosimilars will set the pace of the market in 2015

Jan 12 2015 Biosim

Blog post